We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer and Flynn have been accused of breaking competition law by overcharging the NHS for ‘vital’ anti-epilepsy drugs, according to provisional findings from the UK Competition and Markets Authority (CMA).